Sleep Disorder In Alzheimer Disease
To look at the effect of donepezil on sleep and daily activity in patients with Alzheimer-type
dementia (ATD) using polysomnography and actigraphy. Methods: Ten patients with mild to moderate ATD (mean age: 76 ± 6.2 years) were studied. The Alzheimer's
infection Assessment Scale-psychological segment Japanese form (ADAS-Jcog), polysomnography, and 7-day recording of actigraphy
information were performed. Following this gauge appraisal, donepezil (5 mg day by day) was controlled each morning for about a month and a half, after which the ADAS-Jcog, polysomnography, and actigraphy were rehashed. Results: After about a month and a half of treatment with donepezil, every day movement was altogether expanded(276.2 ± 89.2 vs. 326.1 ± 98.6; p < 0.05). Similarly, rapid eye movement (REM) sleep (11.3 ± 4.1 vs. 17.1 ± 4.4; p and sleep efficiency (76.2 ± 16.3 vs. 82.8 ± 10.6; p<0.05) were significantly increased compared with baseline. Although the ADAS-Jcog score did not decrease significantly (18.5 ± 6.8 vs. 15.9 ± 7.3; P= 0.054), there was a significant positive correlation between the decrease of this score and the increase of daily activity (r= 0.2137, p= 0.4809). Conclusions: An increase of daily activity and
cognition were induced by donepezil treatment in patients with ATD, possibly based on improvement of the sleep structure. In general, elderly persons show changes of their sleep structure due to
aging and such changes are more distinct in patients with Alzheimer-type
dementia (ATD). An increased duration and frequency of waking after sleep onset, a decreased percentage of slow wave sleep and REM sleep, decreased REM density, and sleep-waking cycle disorder that features daytime drowsiness are often seen in ATD patients
High Impact List of Articles
Relevant Topics in General Science